Does availability of hemoglobin A1c results at the point of care make a difference in the clinical care or outcome of the patient with diabetes?

Point of Care

Volumn 5, Issue 2, 2006, Pages 58-61

  Winter, William E ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Box 100275 ^*  (United States)

Author keywords

Diabetic complications; Evidence based medicine; Glycemic control; Hemoglobin A1c

Indexed keywords

EID: 33746611623     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/00134384-200606000-00004     Document Type: Review

References (23)

1. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72.
2. Porter KH, Myers GL. Implications of point-of-care testing for hemoglobin A1c. Diabetes Technol Ther. 2000;2(4):527-528.
3. Lichtenstein LS. Rapid availability of hemoglobin A1c value in the care of patients with diabetes. Endocr Pract. 2001;7:143-144.
4. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315-1321.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
7. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389. [Erratum, N Engl J Med 2000;342:1376].
8. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. December 22, 2005;353(25):2643-2653.
9. American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care. 2006;29:S4-S42.
10. Sicard DA, Taylor JR. Comparison of point-of-care HbA1c test versus standardized laboratory testing. Ann Pharmacother. June 2005;39(6):1024-1028.
11. Stivers CR, Baddam SR, Clark AL, et al. A miniaturized self-contained single-use disposable quantitative test for hemoglobin A1c in blood at the point of care. Diabetes Technol Ther. 2000;2(4):517-526.
12. Kennedy L, Herman WH. Glycated hemoglobin assessment in clinical practice: comparison of the A1cNow point-of-care device with central laboratory testing (GOAL A1C Study). Diabetes Technol Ther. December 2005;7(6):907-912.
13. St John A, Davis TM, Goodall I, et al. Nurse-based evaluation of point-of-care assays for glycated haemoglobin. Clin Chim Acta. September 30, 2005:[Epub ahead of print].
14. Winter WE. Point of care testing in the management of diabetes (chapter 10). In: Nichols JH, ed. Point of Care Testing: Performance Improvement and Evidence Based Outcomes. New York: Marcel Dekker; 2002:235-292.
15. Little RR. Glycated hemoglobin standardization - National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med. September 2003;41(9):1191-1198.
16. Pope RM, Apps JM, Page MD, et al. A novel device for the rapid in-clinic measurement of haemoglobin A1c. Diabet Med. April 1993;10(3):260-263.
17. Thaler LM, Ziemer DC, Gallina DL, et al. Diabetes in urban African-Americans. XVII. Availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care. September 1999;22(9):1415-1421.
18. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. November 1999;22(11):1785-1789.
19. Grieve R, Beech R, Vincent J, et al. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technol Assess. 1999;3(15):1-74.
20. Ferenczi A, Reddy K, Lorber DL. Effect of immediate hemoglobin A1c results on treatment decisions in office practice. Endocr Pract. March-April 2001;7(2):85-88.
21. Miller CD, Barnes CS, Phillips LS, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. April 2003;26(4):1158-1163.
22. Shephard MD, Mazzachi BC, Shephard AK, et al. The impact of point of care testing on diabetes services along Victoria's Mallee Track: results of a community-based diabetes risk assessment and management program. Rural Remote Health. July-September 2005;5(3):371.
23. Available at: http://www.nacb.org/lmpg/poct/chp6_diabetes.pdf. Accessed January 24, 2006.